BioLargo (NASDAQ:BLGO) & Ecovyst (NYSE:ECVT) Critical Contrast

BioLargo (NASDAQ:BLGOGet Free Report) and Ecovyst (NYSE:ECVTGet Free Report) are both small-cap construction companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

BioLargo has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Ecovyst has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 86.7% of Ecovyst shares are owned by institutional investors. 20.3% of BioLargo shares are owned by insiders. Comparatively, 1.6% of Ecovyst shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares BioLargo and Ecovyst’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLargo -16.53% -58.35% -32.12%
Ecovyst 7.74% 7.07% 2.76%

Earnings and Valuation

This table compares BioLargo and Ecovyst”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLargo $12.23 million 4.57 -$3.50 million ($0.02) -9.30
Ecovyst $691.10 million 1.35 $71.15 million $0.46 17.46

Ecovyst has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Ecovyst, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for BioLargo and Ecovyst, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo 0 0 0 0 0.00
Ecovyst 0 0 4 0 3.00

Ecovyst has a consensus price target of $10.50, indicating a potential upside of 30.76%. Given Ecovyst’s stronger consensus rating and higher probable upside, analysts clearly believe Ecovyst is more favorable than BioLargo.

Summary

Ecovyst beats BioLargo on 12 of the 14 factors compared between the two stocks.

About BioLargo

(Get Free Report)

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

About Ecovyst

(Get Free Report)

Ecovyst Inc. offers specialty catalysts and services in the United States and internationally. The company operates in two segments, Ecoservices and Advanced Materials & Catalysts. The Ecoservices segment provides sulfuric acid recycling services and end-to-end logistics for production of alkylate for refineries; and virgin sulfuric acid for mining, water treatment, and industrial applications. The Advanced Materials & Catalysts segment offers advanced materials and specialty catalyst products and process solutions to producers and licensors of polyethylene and advanced silicas. This segment also supplies specialty zeolites and zeolite-based catalysts to customers for refining of oil primarily hydrocracking catalyst and dewaxing, sustainable fuels, and emission control systems for both on-road and non-road diesel engines. The company was formerly known as PQ Group Holdings Inc. and changed its name to Ecovyst Inc. in August 2021. Ecovyst Inc. was founded in 1831 and is headquartered in Malvern, Pennsylvania.

Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.